Soomin Jeong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soomin Jeong has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Anil K. Chokkalla
Department of Neurological Surgery, University of Wisconsin, Madison, WI, USA
3 shared publications - Raghu Vemuganti
Department of Neurological Surgery, University of Wisconsin-Madison, Madison, WI, USA
3 shared publications Bori Kim
Department of Neurological Surgery, University of Wisconsin, Madison, WI, USA
2 shared publications- Charles Kozhikkadan Davis
Department of Neurological Surgery, University of Wisconsin, Madison, WI, USA
2 shared publications Ashlyn Narman
Department of Neurological Surgery (S.J., A.K.C., C.K.D., B.C., V.A., B.K., A.N., S.B., R.V.), University of Wisconsin, Madison
1 shared publication- Awurama Akyianu
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3820-3831
Targeted LNP-mediated delivery of VE-cadherin mRNA reduces vascular hyperpermeability in vivo
Blood vessel hyperpermeability underlies a wide spectrum of potentially fatal diseases, ranging from acute pulmonary edema to brain injuries such as ischemic stroke. However, effective strategies for rapid rehabilitation of the vascular endothelium to restore vascular homeostasis remain lacking. Here, we developed a messenger RNA (mRNA) therapeutic encoding the vascular membrane structural protein vascular endothelial-cadherin (VEc), delivered via an anti-CD31 targeted lipid nanoparticle (aCD31/tLNP-VEc) directly to CD31+ vascular endothelial cells, for the rapid restoration of vascular integrity. We showed that administration of a single dose of aCD31/tLNP-VEc significantly ameliorates pathological onset in multiple mouse models of vascular hyperpermeability. In a bleomycin-induced lung edema model, we found aCD31/tLNP-VEc treatment significantly reduced fluid extravasation and decreased macrophage infiltration. In a transient middle cerebral artery occlusion-induced ischemic stroke model, aCD31/tLNP-VEc delivered postinjury diminished plasma protein leakage associated with brain edema by 50%. Targeted LNP-mediated delivery of VEc mRNA to the vascular network presents a promising platform for treating clinically relevant conditions involving vascular disruption.
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3820-3831
Open AccessTargeted LNP-mediated delivery of VE-cadherin mRNA reduces vascular hyperpermeability in vivo
Blood vessel hyperpermeability underlies a wide spectrum of potentially fatal diseases, ranging from acute pulmonary edema to brain injuries such as ischemic stroke. However, effective strategies for rapid rehabilitation of the vascular endothelium to restore vascular homeostasis remain lacking. Here, we developed a messenger RNA (mRNA) therapeutic encoding the vascular membrane structural protein vascular endothelial-cadherin (VEc), delivered via an anti-CD31 targeted lipid nanoparticle (aCD31/tLNP-VEc) directly to CD31+ vascular endothelial cells, for the rapid restoration of vascular integrity. We showed that administration of a single dose of aCD31/tLNP-VEc significantly ameliorates pathological onset in multiple mouse models of vascular hyperpermeability. In a bleomycin-induced lung edema model, we found aCD31/tLNP-VEc treatment significantly reduced fluid extravasation and decreased macrophage infiltration. In a transient middle cerebral artery occlusion-induced ischemic stroke model, aCD31/tLNP-VEc delivered postinjury diminished plasma protein leakage associated with brain edema by 50%. Targeted LNP-mediated delivery of VEc mRNA to the vascular network presents a promising platform for treating clinically relevant conditions involving vascular disruption.
- 15 May 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 45 (10) , 1877-1890
FTO promotes post-stroke neuroprotection by m 6 A demethylation of c-Jun
N 6 -methyladenosine (m 6 A) is a critical epitranscriptomic regulator of neuronal function. Cerebral ischemia induces m 6 A hypermethylation due to decreased expression of m 6 A demethylase fat mass and obesity-associated (FTO) protein. Previously, we showed that cerebral overexpression of FTO with an adeno-associated virus (AAV) 9 protects the post-stroke brain. We presently evaluated the mechanistic basis for FTO-dependent m 6 A demethylation in post-ischemic neuroprotection using the mice transient middle cerebral artery occlusion model of experimental stroke. Based on the bioinformatic predictions and m 6 A abundance, pro-apoptotic transcription factor Jun proto-oncogene (c-Jun) with 19 m 6 A sites was chosen as an exemplary target. FTO overexpression normalized the post-stroke m 6 A hypermethylation of c-Jun without altering its transcript levels. FTO-dependent m 6 A demethylation suppressed translation of c-Jun. Consequently, several c-Jun target genes are transcriptionally repressed, and the post-ischemic neuronal apoptosis is decelerated, as seen by decreased cleaved caspase-3 levels and TUNEL + neurons in the FTO AAV9 treated group compared to the control AAV9 treated group. Moreover, replenishing c-Jun precluded the FTO-mediated post-stroke neuroprotection and functional recovery. Collectively, this study demonstrated that the FTO/m 6 A/c-Jun axis ameliorates post-stroke neuronal apoptosis and brain damage, leading to better functional outcomes.
- 15 May 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 45 (10) , 1877-1890
FTO promotes post-stroke neuroprotection by m 6 A demethylation of c-Jun
N 6 -methyladenosine (m 6 A) is a critical epitranscriptomic regulator of neuronal function. Cerebral ischemia induces m 6 A hypermethylation due to decreased expression of m 6 A demethylase fat mass and obesity-associated (FTO) protein. Previously, we showed that cerebral overexpression of FTO with an adeno-associated virus (AAV) 9 protects the post-stroke brain. We presently evaluated the mechanistic basis for FTO-dependent m 6 A demethylation in post-ischemic neuroprotection using the mice transient middle cerebral artery occlusion model of experimental stroke. Based on the bioinformatic predictions and m 6 A abundance, pro-apoptotic transcription factor Jun proto-oncogene (c-Jun) with 19 m 6 A sites was chosen as an exemplary target. FTO overexpression normalized the post-stroke m 6 A hypermethylation of c-Jun without altering its transcript levels. FTO-dependent m 6 A demethylation suppressed translation of c-Jun. Consequently, several c-Jun target genes are transcriptionally repressed, and the post-ischemic neuronal apoptosis is decelerated, as seen by decreased cleaved caspase-3 levels and TUNEL + neurons in the FTO AAV9 treated group compared to the control AAV9 treated group. Moreover, replenishing c-Jun precluded the FTO-mediated post-stroke neuroprotection and functional recovery. Collectively, this study demonstrated that the FTO/m 6 A/c-Jun axis ameliorates post-stroke neuronal apoptosis and brain damage, leading to better functional outcomes.
- 7 February 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 45 (4) , 779-789
Fecal microbiota transplantation fails to impart the benefits of circadian-dependent intermittent fasting following ischemic stroke
Intermittent fasting (IF) is known to induce significant ischemic tolerance. Diet is a major proponent of gut microbiota, and gut microbial dysbiosis plays a role in post-stroke brain damage. Hence, we currently evaluated whether IF-mediated ischemic tolerance is mediated by gut microbiota. Additionally, circadian cycle is known to modulate post-ischemic outcomes, and thus we further evaluated if gut microbiota would be influenced by prophylactic IF during the inactive phase (fasting during daytime; IIF) or active phase (fasting during nighttime; AIF). The AIF, but not IIF, cohort showed a significantly decreased fecal Firmicutes/Bacteroidetes ratio compared with the ad libitum (AL) cohort. Moreover, the levels of gut microbiota-derived metabolites butyrate and propionate decreased in AL cohort following focal ischemia, whereas they increased in AIF cohort. However, fecal microbiota transplantation (FMT) from IIF or AIF cohort had no significant effects on post-ischemic motor and cognitive function recovery, anxiety-, and depression-like behaviors compared with FMT from AL cohort. Furthermore, FMT from IIF or AIF cohort did not influence the post-ischemic infarct volume, atrophy volume or white matter damage. Overall, the current findings indicate that the beneficial effects of IF after focal ischemia are not mediated by the gut microbiota.
- 7 February 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 45 (4) , 779-789
Fecal microbiota transplantation fails to impart the benefits of circadian-dependent intermittent fasting following ischemic stroke
Intermittent fasting (IF) is known to induce significant ischemic tolerance. Diet is a major proponent of gut microbiota, and gut microbial dysbiosis plays a role in post-stroke brain damage. Hence, we currently evaluated whether IF-mediated ischemic tolerance is mediated by gut microbiota. Additionally, circadian cycle is known to modulate post-ischemic outcomes, and thus we further evaluated if gut microbiota would be influenced by prophylactic IF during the inactive phase (fasting during daytime; IIF) or active phase (fasting during nighttime; AIF). The AIF, but not IIF, cohort showed a significantly decreased fecal Firmicutes/Bacteroidetes ratio compared with the ad libitum (AL) cohort. Moreover, the levels of gut microbiota-derived metabolites butyrate and propionate decreased in AL cohort following focal ischemia, whereas they increased in AIF cohort. However, fecal microbiota transplantation (FMT) from IIF or AIF cohort had no significant effects on post-ischemic motor and cognitive function recovery, anxiety-, and depression-like behaviors compared with FMT from AL cohort. Furthermore, FMT from IIF or AIF cohort did not influence the post-ischemic infarct volume, atrophy volume or white matter damage. Overall, the current findings indicate that the beneficial effects of IF after focal ischemia are not mediated by the gut microbiota.
- 1 August 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (8) , 2139-2150
Circadian-Dependent Intermittent Fasting Influences Ischemic Tolerance and Dendritic Spine Remodeling
BACKGROUND: Preconditioning by intermittent fasting is linked to improved cognition and motor function, and enhanced recovery after stroke. Although the duration of fasting was shown to elicit different levels of neuroprotection after ischemic stroke, the impact of time of fasting with respect to the circadian cycles remains unexplored. METHODS: Cohorts of mice were subjected to a daily 16-hour fast, either during the dark phase (active-phase intermittent fasting) or the light phase (inactive-phase intermittent fasting) or were fed ad libitum. Following a 6-week dietary regimen, mice were subjected to transient focal cerebral ischemia and underwent behavioral functional assessment. Brain samples were collected for RNA sequencing and histopathologic analyses. RESULTS: Active-phase intermittent fasting cohort exhibited better poststroke motor and cognitive recovery as well as reduced infarction, in contrast to inactive-phase intermittent fasting cohort, when compared with ad libitum cohort. In addition, protection of dendritic spine density/morphology and increased expression of postsynaptic density protein-95 were observed in the active-phase intermittent fasting. CONCLUSIONS: These findings indicate that the time of daily fasting is an important factor in inducing ischemic tolerance by intermittent fasting.
- 1 August 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (8) , 2139-2150
Circadian-Dependent Intermittent Fasting Influences Ischemic Tolerance and Dendritic Spine Remodeling
BACKGROUND: Preconditioning by intermittent fasting is linked to improved cognition and motor function, and enhanced recovery after stroke. Although the duration of fasting was shown to elicit different levels of neuroprotection after ischemic stroke, the impact of time of fasting with respect to the circadian cycles remains unexplored. METHODS: Cohorts of mice were subjected to a daily 16-hour fast, either during the dark phase (active-phase intermittent fasting) or the light phase (inactive-phase intermittent fasting) or were fed ad libitum. Following a 6-week dietary regimen, mice were subjected to transient focal cerebral ischemia and underwent behavioral functional assessment. Brain samples were collected for RNA sequencing and histopathologic analyses. RESULTS: Active-phase intermittent fasting cohort exhibited better poststroke motor and cognitive recovery as well as reduced infarction, in contrast to inactive-phase intermittent fasting cohort, when compared with ad libitum cohort. In addition, protection of dendritic spine density/morphology and increased expression of postsynaptic density protein-95 were observed in the active-phase intermittent fasting. CONCLUSIONS: These findings indicate that the time of daily fasting is an important factor in inducing ischemic tolerance by intermittent fasting.